AJMC February 11, 2022
Bruce Feinberg, DO, Mark G. Kris, MD, Kenna R. Mills Shaw, PhD, Eugean Jiwanmall, MPH, MBA

The rationale for migrating away from single, spot testing to comprehensive genomic profiling assays in oncology.

Bruce Feinberg, DO: I keep stepping back, taking the one step back because I don’t want to lose our audience. But for most of the audience, they probably are more familiar with NGS [next-generation sequencing] than they are with CGP [comprehensive genomic profiling]. But NGS is the method and CGP is the outcome of that method, if I might think of it that way. But if you could go into it, into a little bit more depth and distinguish between what we were doing in terms of a single test, and looking for potentially a protein vs the gene....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Conferences / Podcast, Pharma / Biotech, Physician, Precision Medicine, Provider, Trends
Dr. Amar Naik and Shrinking the Knowing/Doing Gap in GI Care
Seniors deserve timely access to care, not bureaucratic hurdles | Viewpoint
Doctors at the forefront of health care reform [PODCAST]
Digital Doctors Are Coming. Regulators Need to Catch Up.
Belief in God: Medicine’s guiding light through every challenge

Share This Article